Stoke Therapeutics Inc Stock
Stoke Therapeutics Inc Stock
Stoke Therapeutics Inc dominated the market today, gaining €1.80 (6.870%).
With 19 Buy predictions and not the single Sell prediction the community is currently very high on Stoke Therapeutics Inc.
With a target price of 33 € there is a slightly positive potential of 13.01% for Stoke Therapeutics Inc compared to the current price of 29.2 €.
So far the community has only identified positive things for Stoke Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Stoke Therapeutics Inc in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Stoke Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | 6.870% | 9.774% | 33.945% | 135.484% | 175.472% | - | - |
| Personalis Inc | -6.360% | -16.991% | 8.098% | 118.823% | 35.050% | 206.982% | -76.345% |
| Immuron | 1.910% | -37.008% | -41.176% | -56.284% | -51.220% | -57.447% | -86.325% |
Comments
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $22.00 to $32.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics (NASDAQ:STOK) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $39.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at BTIG Research from $28.00 to $39.00. They now have a "buy" rating on the stock.
Show more
Ratings data for STOK provided by MarketBeat